Please assess the completion status of the following clinical trial:

Trial Title: Clonidine for Neonatal Abstinence Syndrome Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 0 to 15 days of age~* Prenatal exposure to opioids with development of moderate to severe NAS (2 consecutive abstinence scores of ≥ 8)~* Medically stable~Exclusion Criteria:~* Gestational age \< 35 weeks~* Intrauterine growth retardation (birth weight below the 5th percentile)~* Congenital heart disease~* Congenital anomalies~* Medically unstable~Exposure to Benzodiazepines prenatally~-

- Gender: ALL
- Minimum Age: None
- Maximum Age: 15 Days
- Healthy Volunteers: f

Study Arms:
- NMS/Clonidine (Type: EXPERIMENTAL): None
- NMS/Phenobarbital (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).